ClinicalTrials.gov
public full text
Public Domain
Piclidenoson for Treatment of COVID-19
Patients with documented moderate COVID-19 infection will be randomized 1:1 to receive piclidenoson 2 mg Q12H orally with standard supportive care (SSC - intervention arm) or placebo orally with SSC (control arm) for up to 28 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- New Antiviral Drugs for Treatment of COVID-19#158058
- Colchicine in Moderate Symptomatic COVID-19 Patients#834284
- ZYESAMI (Aviptadil) Intermediate Population Expanded Access Protocol (SAMICARE)#882376
- Which healthcare services did children and adolescents use before presentation at specialised outpatient clinics for post-COVID-19 condition? Descriptive findings from the Post-COVID Kids Bavaria study.#25513
- Corticosteroid Combining Noncorticosteroid Systemic Immunomodulatory Therapy in VKH#885232
Record · ID 1165253
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive